LON:AGL - ANGLE Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: N/A
Consensus Price Target: GBX 0
Forecasted Upside: -100.00 %
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

GBX 107.50 As of 08/2/2021 01:00 AM ET

▼ -1.75 (-1.60%)

1 month | 3 months | 12 months

Get New ANGLE Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGL

GBX 0

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for ANGLE in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 107.50.

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in ANGLE. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/10/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/10/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/8/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/6/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/4/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/5/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/4/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/3/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target
7/20/2020	FinnCap	Reiterated Rating	Corporate
6/22/2020	FinnCap	Reiterated Rating	Corporate
5/12/2020	FinnCap	Reiterated Rating	Corporate
4/28/2020	FinnCap	Reiterated Rating	Corporate
4/17/2020	FinnCap	Reiterated Rating	Corporate
3/31/2020	FinnCap	Reiterated Rating	Corporate
2/27/2020	FinnCap	Reiterated Rating	Corporate
1/30/2020	FinnCap	Reiterated Rating	Corporate
1/22/2020	FinnCap	Reiterated Rating	Corporate
10/30/2019	FinnCap	Reiterated Rating	Corporate
9/10/2019	FinnCap	Reiterated Rating	Corporate
7/31/2019	FinnCap	Reiterated Rating	Corporate
6/26/2019	FinnCap	Reiterated Rating	Corporate
5/31/2019	FinnCap	Reiterated Rating	Corporate
4/26/2019	FinnCap	Reiterated Rating	Corporate
4/18/2019	FinnCap	Reiterated Rating	Corporate
3/7/2019	FinnCap	Reiterated Rating	Corporate
2/25/2019	FinnCap	Reiterated Rating	Corporate
1/31/2019	FinnCap	Reiterated Rating	Corporate
1/11/2019	FinnCap	Reiterated Rating	Corporate
11/5/2018	FinnCap	Reiterated Rating	Corporate
10/25/2018	FinnCap	Reiterated Rating	Corporate
7/25/2018	FinnCap	Reiterated Rating	Corporate
6/26/2018	FinnCap	Boost Price Target	Corporate	GBX 108 ➝ GBX 110
4/19/2018	FinnCap	Reiterated Rating	Corporate	GBX 108
4/5/2018	FinnCap	Reiterated Rating	Corporate
3/26/2018	FinnCap	Reiterated Rating	Corporate	GBX 108
2/12/2018	FinnCap	Reiterated Rating	Corporate	GBX 108
1/31/2018	FinnCap	Reiterated Rating	Corporate	GBX 108
1/8/2018	FinnCap	Reiterated Rating	Corporate	GBX 108
11/21/2017	FinnCap	Reiterated Rating	Corporate	GBX 108
10/23/2017	FinnCap	Reiterated Rating	Corporate	GBX 108
10/9/2017	FinnCap	Reiterated Rating	Corporate	GBX 108 ➝ GBX 100
9/11/2017	FinnCap	Reiterated Rating	Corporate	GBX 100
9/5/2017	FinnCap	Initiated Coverage	Corporate	GBX 100
7/5/2017	Beaufort Securities	Reiterated Rating	Speculative Buy
6/16/2017	Beaufort Securities	Reiterated Rating	Speculative Buy
6/6/2017	Beaufort Securities	Reiterated Rating	Speculative Buy
5/4/2017	Beaufort Securities	Reiterated Rating	Speculative Buy
3/31/2017	Beaufort Securities	Reiterated Rating	Speculative Buy
2/14/2017	Beaufort Securities	Reiterated Rating	Speculative Buy
1/27/2017	Beaufort Securities	Reiterated Rating	Speculative Buy
11/7/2016	Beaufort Securities	Reiterated Rating	Speculative Buy

(Data available from 8/3/2016 forward)

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products worldwide. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and HyCEAD multiplex analysis system used as the downstream analysis tool in the ovarian cancer clinical application. It also offers specialist circulating tumor cell enrichment and analysis services to support translational research studies and pharmaceutical trials. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Today's Range

Now: GBX 107.50

106.03

110

50 Day Range

MA: GBX 124.14

107.50

139

52 Week Range

Now: GBX 107.50

37.15

143.90

Volume

336,374 shs

Average Volume

972,152 shs

Market Capitalization

£250.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ANGLE?

The following Wall Street analysts have issued reports on ANGLE in the last year:
View the latest analyst ratings for AGL.

What is the current price target for ANGLE?

0 Wall Street analysts have set twelve-month price targets for ANGLE in the last year. has the lowest price target set, forecasting a price of £100,000 for ANGLE in the next year.
View the latest price targets for AGL.

What is the current consensus analyst rating for ANGLE?

ANGLE currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AGL.

What other companies compete with ANGLE?

Other companies that are similar to ANGLE include Phathom Pharmaceuticals, Antibe Therapeutics, Caribou Biosciences, SI-BONE, Coherus BioSciences, Cano Health, Phibro Animal Health, Vaxart, OrganiGram, DermTech, Olema Pharmaceuticals, CytoDyn, Hanger, Tactile Systems Technology and (THCX.V).

How do I contact ANGLE's investor relations team?

ANGLE's physical mailing address is The Surrey Research Park 3 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company's listed phone number is +44-1483-685830. The official website for ANGLE is www.angleplc.com.